Ads
related to: treatment for carcinoid tumors injection- Dosing & Administration
Healthcare Professionals: See How
Your Patients May Receive Treatment
- Mechanism Of Action
MOA For A Therapy In Multiple
Metastatic Solid Tumor Types.
- Identifying Patients
Discover Patient Identification &
IHC Info. Will You Take Action?
- Official Physician Site
Visit Site For A Treatment
Option For Metastatic Solid Tumors.
- Access Data & Results
View Data To See If A Treatment For
Metastatic Solid Tumors May Help.
- Request A Contact
Complete A Brief Form To Receive
Updates For A Treatment Option.
- Dosing & Administration
Search results
Results From The WOW.Com Content Network
Lanreotide is used in the treatment of acromegaly, due to both pituitary and non-pituitary growth hormone-secreting tumors, and the management of symptoms caused by neuroendocrine tumors, particularly carcinoid tumors and VIPomas. In the United States and Canada, lanreotide is only indicated for the treatment of acromegaly.
It was previously used in the treatment of breast cancer, but has been replaced by more effective and less toxic agents. Estrace is an estrogen which was also formerly used for antiandrogen therapy of prostate cancer. [2] Polyestradiol phosphate is a long-acting derivative of estradiol that is applied as an intramuscular injection.
An octreotide scan is a type of SPECT scintigraphy used to find carcinoid, pancreatic neuroendocrine tumors, and to localize sarcoidosis. It is also called somatostatin receptor scintigraphy (SRS). Octreotide , a drug similar to somatostatin , is radiolabeled with indium-111 , [ 1 ] and is injected into a vein and travels through the bloodstream.
Octreotide is used for the treatment of growth hormone producing tumors (acromegaly and gigantism), when surgery is contraindicated, pituitary tumors that secrete thyroid-stimulating hormone (thyrotropinoma), [citation needed] diarrhea and flushing episodes associated with carcinoid syndrome, and diarrhea in people with vasoactive intestinal peptide-secreting tumors ().
Treatments have improved over the past several decades, and outcomes are improving. [49] In malignant carcinoid tumors with carcinoid syndrome, the median survival has improved from two years to more than eight years. [75] Detailed guidelines for managing neuroendocrine tumors are available from ESMO, [76] NCCN [77] and a UK panel. [1]
A carcinoid (also carcinoid tumor) is a slow-growing [1] type of neuroendocrine tumor originating in the cells of the neuroendocrine system. In some cases, metastasis may occur. Carcinoid tumors of the midgut ( jejunum , ileum , appendix , and cecum ) are associated with carcinoid syndrome .